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Growth retardation is a major complication of the
use of long-term steroid therapy in children [1]. Dai-
ly steroid therapy has profound effects on growth;
alternate day therapy has less 12]. The mechanisms
by which steroids inhibit growth are many. The re-
view of how glucocorticoids may inhibit cell prolif-
eration and growth points out the many cell mecha-
nisms vulnerable to steroid effect: depression of cell
energy metabolism and direct effects on cell recep-
tor sites that modify either RNA or protein syn-
thesis [3—5] (see Baxter, this issue).
Animal models also have been useful in investi-
gating steroid effects on growth. Following short-
term administration that inhibits growth. catch-up
growth occurs similar to that seen in recovery from
malnutrition [6]. Accelerated growth includes spe-
cific organ systems as well as whole body. Catch-up
growth on stopping steroid therapy is not in-
variable. Large doses given over long periods can
result in irreversible growth retardation which is
more easily induced at less mature stages of devel-
opment either in children or in experimental ani-
mals [3].
Children with kidney disease who are likely to be
given growth suppressive doses of steroids fall into
two general groups—those with the nephrotic syn-
drome or some type of glomerulonephritis, and
those who have received a renal transplant. In this
report, we present some clinical observations of a
child with nephrosis who was treated long-term
with prednisone and became irreverisbly growth-re-
tarded. From this example, certain points emerge
that illustrate some common problems in using
steroid therapy for children with the nephrotic syn-
drome or other glomerulopathies. We also review
growth performance of children after renal trans-
plant, and we discuss, from a clinical perspective,
how steroid therapy may affect growth.
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Steroid suppression of growth in children with the
nephrotic syndrome
Alternate-day steroid therapy generally is thought
to have little effect on growth when it is used in
treatment of the nephrotic syndrome. While meta-
bolic and nutritional consequences of nephro-
sis may interfere with growth, the usual steroid-de-
pendent case is not likely to have proteinuria and
edema sufficient to affect growth and is a relatively
good model for examining growth-suppressing ef-
fects of steroids in children. The following case is
illustrative.
Case report
The patient had shown normal growth and development until
the age of 2.6 yr, when he developed the nephrotic syndrome
(Fig. IA). The initial clinical picture was not associated with
hematuria, hypertension, or azotemia. A percutaneous renal
biopsy demonstrated "minimal change disease" ("nil" lesion).
Daily prednisone therapy (60 mg/m2/day) resulted in prompt diur-
esis and clearing of the proteinuria within 3 weeks. Daily therapy
was given for a total of 4 weeks, then was changed to 40 mg/m2/
day given in divided dosages on 3 consecutive days of each
week. Two weeks after beginning this maintenance therapy, he
had an exacerbation of his nephrotic syndrome, necessitating
reinstitution of daily prednisone therapy. Remission was induced
within 10 days, and maintenance therapy was once again started,
but another exacerbation occurred after 5 weeks. From 2.6 until
5.7 yr (Fig. 1, A-B), the patient experienced multiple recurrences
of his disease, and, except for one 12-week period, he was con-
stantly receiving steroid therapy in various doses and schedules
of administration. Stature for age fell from the 50th, to below the
3rd percentile for age; weight, by contrast, increased to the 95th
percentile for age.
At 5.7 yr (Fig. 1, point B). despite this course, the patient had
normal renal function. He was given cyclophosphamide for 12
weeks (2.1 mg/kg/day), and steroids were discontinued. From
then until 7.8 yr of age—a period of 2.1 years (108 weeks)—he
did not have a recurrence and received no therapy (Fig. 1, B-C).
Growth rate increased, and some catch-up growth occurred.
Stature for age, however, stabilized in the 10th percentile rather
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Fig. 1. Growth and development of male child with nephrotic
syndrome.
than the level before illness of 50th percentile for age. An ex-
acerbation of the nephrotic syndrome occurred at 7.8 yr, which
responded to daily steroid administration. A frequently relapsing
course returned and has continued despite constant alternate
morning steroid administration and intermittent courses of daily
steroids. Once again, growth rate decreased (Fig. 1, C-D).
This example demonstrates several points of im-
portance concerning steroid administration in chil-
dren with kidney disease. Significant growth inhibi-
tion occurred, even in the absence of deteriorating
renal function and in spite of attempts to limit the
amount of daily therapy. During the 2.9 yr (150
weeks) between onset of nephrosis and institution
of cyclophosphamide (Fig. 1), the patient received
daily therapy for only 30 weeks while receiving in-
termittent therapy (3 day/week, divided dose, or a!-
ternate morning single dose) for 108 weeks, and no
therapy for 12 weeks. Despite the fact that he was
not in ill health during most of this time and under-
nutrition was obviously not a problem, he only
gained 12 or 23 cm, or 54%, needed to achieve nor-
mal stature for his age.
It is not surprising that growth retardation oc-
curred during the periods the child received daily
therapy in doses given. Early studies jjl—2j have
demonstrated that daily steroid therapy, in doses
appreciably less than his, were associated with
growth retardation [11.
The poor growth the child experienced when he
received alternate day therapy is less rapidly ex-
plained in view of the normal growth reported in
children with asthma given alternate-day therapy
230 [2]. Alternate-day therapy in experimental animal
-220 models also had no growth inhibiting effects [7].
Chesney et al [8], however, recently reported re-
.' suIts of alternate-day therapy (2.5 mg/kg) in 25 chil-
180 ' dren with renal disease who did not have impaired
function (GFR). Of these 25 children 18 had de-
-iso ' creased growth rates; this finding was associated
140 with poor bone mineralization.
Low concentrations of glucocorticoids are suf-
-ito ficient to suppress growth hormone levels and pos-
sible somatomedin action [4, 5]. Small changes in
-80 metabolic clearance of prednisone may occur in the
-70 nephrotic syndrome that prolong the glucocorticoid
effect. This and slightly different dose schedules
-40 may account for the growth retardation seen in
these children in contrast to what is seen in those
with asthma. It is also possible that proteinuria or
edema, or both may affect growth although moder-
ate proteinuria usually has little physiological effect
and gross edema is uncommon in children who re-
spond to treatment. Although alternate-day therapy
had no effect in the experimental model reported
[71, there is difficulty in assuming that the dose
schedule used can be equated to that given children
with kidney disease.
The patient did exhibit catch-up growth when he
no longer received steroids. Growth of 15 cm is
greater than the 13 that is normal for his age for that
period. It is, however, less than the 23 cm the child
needed to return to the normal stature percentile for
age. This is consistent with earlier experience and
reflects both the immature age of the child at time of
treatment and the intensity and duration of treat-
me nt.
In summary, children with nephrosis or glomeru-
lar disease who receive alternate-day steroid thera-
py are at risk to growth retardation which may be
permanent. The poor growth is associated with
poor bone mineralization.
Steroid therapy after renal transplantation
The factors affecting growth in children after
transplant include the use of either daily or alter-
nate-day steroid therapy, the child's growth poten-
tial at the time of transplantation [9], and the ade-
quacy of function of the transplanted kidney [101.
Growth potential is predicted from a child's stature
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percentiles for both chronological age and bone age
[11].
Results in growth after transplant have varied.
Potter et al [12] reported that children who receive
less than 8.5 mg of prednisone/m2/day grow better
than those who receive a higher dose. Saenger et a!
[10] noted better growth in children who receive
less than 6.5 mg/m2/day. Lilly et al [131 and De-
Shazo et al [141 reported normal growth for age in
50% and 87% of children, respectively, who were
treated with daily prednisone. Pennisi et al [15]
noted that only 13% of their long-term transplant
recipients grew more than 80% of expected height
for age. These latter authors surmised that the dif-
ference in growth between their patients and those
studied previously could be explained by dif-
ferences in steroid dose around 1 yr after transplant:
approximately 0.2 to 0.3 mg/kg/day in those with
better growth [13, 14] in contrast to 0.56 mg/kg/day
with poorer growth [15].
Growth appears to be better when prednisone is
given as a single dose on alternate days than when it
is given in divided doses daily. Between 30 and
100% of children using this regimen grew at normal
rates for age [16-19].
No controlled studies have been reported com-
paring growth performance and renal function in
children treated either with daily or alternate day
therapy.
Mechanisms of steroid inhibition of growth in children
Studies in children that focus on mechanisms of
steroid inhibition of growth are few. The influence
of steroids on cell metabolism point to many theo-
retical possibilities (see Baxter, this issue). The
finding of an association between bone mineral-
ization and poor growth raises some other possi-
bilities as to how steroids might inhibit growth.
Steroid therapy depresses calcium absorption [20],
decreases serum concentrations of 25-hydroxy-
vitamin D [20], and increases secretion of para-
thyroid hormone [21]. Each of these effects may af-
fect bone mineralization, which may affect growth.
Phosphate depletion may also occur with steroid
therapy, particularly when given to a child after re-
nal transplantation. Children with hypophosphatem-
ic rickets improve growth when phosphate is given
[22]. Hypophosphatemia may occur after trans-
plant, and a number of factors may contribute to its
development. Substituting a functioning for a non-
functioning kidney in a person with secondary hy-
perparathyroidism results in a phosphate diuresis
[23]. Glucocorticoids increase renal phosphate ex-
cretion [24], probably by stimulating parathormone
secretion and decreasing tubular reabsorption of
phosphate [21]. Whatever the mechanisms, the
phosphaturia common in children after transplant
[25] may contribute to growth retardation. This ef-
fect, however, is likely to be short-lived, whereas
growth-inhibiting effects prevail for long periods.
In summary, steroid therapy, including alternate-
day steroid therapy, has the capacity to inhibit
growth and cause bone dernineralization in children
with kidney disease—especially those with steroid-
dependent nephrotic syndrome and those who have
undergone renal transplantation. The effect is less
on alternate-day therapy. There is evidence that
steroid effects upon phosphorus and calcium may
contribute to bone demineralization and to growth
inhibition. Glucocorticoids, however, may inhibit
growth in any of several ways, including direct ac-
tion on cell growth. The rate-limiting step for
growth of children most readily inhibited by steroid
therapy is not known. When identified, a key will be
available for pacing therapy to avoid growth retar-
dation. For the present, the minimum therapy nec-
essary to achieve the desired clinical result still
seems capable of inhibiting growth.
Summary
Glucorticoid therapy inhibits statural growth. Al-
ternate-day therapy causes less growth suppression
than does daily therapy, and, in experimental ani-
mals and children with asthma, it has been associat-
ed with normal growth. Although catch-up growth
may occur after cessation of steroid therapy, this is
not always the case, especially when therapy has
been prolonged. In children treated with steroids
for glomerulonephritis or nephrotic syndrome and
especially in children after renal transplantation,
factors other than steroid therapy may contribute to
growth retardation. Steroids may suppress growth
by direct action on cell metabolism, by inhibition of
growth hormone or somatomedin and/or by effects
on calcium and phosphorus metabolism. Present
knowledge of mechanisms of action and dose-re-
sponse relationships is incomplete, and it is difficult
to prescribe therapy which will achieve a predict-
able therapeutic effect without inhibiting growth.
Reprint requests to Dr. L. Travis, University of Texas Medical
Branch, Galveston, Texas 77550, U.S A.
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